Pharmacoscopy for Patients With Refractory Primary Brain Tumors

Prior treatment

• Concurrent treatment with other systemic tumor-directed pharmacotherapies.
• Intent to be treated with radiotherapy.
• Any investigational antitumor therapy other than those under investigation in this study.
• Women who are breast feeding and who do not agree to discontinue nursing prior to the first study treatment and for the period defined in the protocol.

Lab values

• Intention to become pregnant during the course of the study or pregnancy. Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test.

Other

• Inability to undergo brain or spine MRI.
• Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures, restrictions and requirements.
• Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.

• Age 18 years or older on day of signing informed consent, female or male.
• Refractory glioblastoma, isocitrate dehydrogenase (IDH)-mutant astrocytoma or oligodendroglioma, histone-mutant glioma, ependymoma, medulloblastoma, meningioma or other rare primary brain tumor with a histological confirmation according to the WHO classification 2021. Primary tumors can be located at the cerebral or spinal level. Primary brain tumors with metastases outside of the brain may also be considered.
• Karnofsky performance status of 60 or more
• Life expectancy \>12 weeks.
• Limited systemic therapeutic options as per treating physician judgement. The number of previous lines of therapies is not limited.
• Surgery clinically indicated. A histological confirmation of the diagnosis of a recurrent brain tumor will be required before any treatment can be initiated.
• Adequate bone marrow, renal and hepatic function
• Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
• Written informed consent for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.